Print Options

Font size:

← Back to notecard set|Easy Notecards home page

Print this list...Print as notecards

Chapter 74 IBD

1.

Define IBD

group of inflammatory conditions of the colon and small intestine

2.

Major types of IBD

ulcerative colitis and Crohn's disease

3.

ulcerative colitis characteristics

mucosal inflammation confined to the rectum and colon with superficial ulcerations

4.

when UC is limited to the descending colon and rectum, it is called

distal disease and can be treated with topical (rectal) treatment

5.

in UC, inflammation limited to the rectum is called

proctitis

6.

characteristics of moderate UC

characterized by >4 stools/day with minimal signs of toxicity

7.

characteristics of severe UC

≥ 6 bloody stools/day with evidence of toxicity (fever, tachycardia, anemia, elevated ESR)

8.

characteristics of fulminant UC

>10 stools/day and severe symptoms (continuous bleeding, abdominal pain, distension)

9.

characteristics of Crohn's disease

characterized by deep, transmural (through the bowel wall) inflammation that can affect any part of the GI tract

10.

in Crohn's disease, what part of the GI tract like likely affected

ileum and colon

11.

symptoms of Crohn's disease

chronic diarrhea (nocturnal), abdominal pain and weight loss

12.

pattern of Crohn's disease

non-continuous, "cobblestone" appearance

13.

pattern of UC

continuous

14.

location of Crohn's disease

entire GI tract (especially ileum and colon)

15.

location of UC

colon (especially the rectum)

16.

depth of Crohn's disease

transmural

17.

depth of UC

superficial

18.

True or false. Fistulas/strictures are common in Crohn's disease.

True

19.

True or false. Fistulas/strictures are common in UC.

False. They are uncommon

20.

Smoking is a ____ for Crohn's disease

risk factor

21.

Smoking is a ____ measure for UC

protective

22.

How is IBD diagnosed

colonoscopy with tissue biopsy

23.

What class of medications are used for maintenance therapy in most patients with distal UC or mild extensive disease

aminosalicylates

24.

What medication is used for mild Crohn's disease

oral budesonide ≤ 3 months, after this course, discontinue treatment or change to thiopurine or methotrexate

25.

What medications are used for moderate to severe Crohn's disease

anti-TNF agents (humira, remicade, cimzia), thiopurines, methotrexate, IL receptor antagonist (stelara)

26.

What medications are used for refractory to standard treatment in Crohn's disease

Entyvio, Tysabri

27.

What medication is used for mild UC

mesalamine (5-ASA) rectal and/or oral preferred

28.

What medications are used for moderate to severe UC

anti-TNF agents (humira, remicade, simponi), thiopurines, cyclosporines, IL receptor antagonist (stelara)

29.

What medications are used for refractory to standard treatment for UC

entyvio, xeljanz

30.

Brand name for budesonide used for CD

Entocort EC

31.

Brand name for budesonide used for UC

Uceris

32.

How is budesonide metabolized

undergoes extensive first-pass metabolism, decreases systemic exposure than other oral steroids

33.

Rectal steroids are indicated for

UC only

34.

Brand name for hydrocortisone rectal

Cortenema, Cortifoam

35.

Primary aminosalicylate used for UC

mesalamine

36.

Sulfasalazine is used less commonly due to the

many side effects associated with the sulfapyridine component

37.

Brand name for sulfasalazine

Azulfidine

38.

Azathioprine is metabolized to

mercaptopurine

39.

What test should be considered before starting azathioprine

TPMT genetic testing

40.

Brand name for azathioprine

Azasan, Imuran

41.

Brand name of ustekinumab

Stelara

42.

MOA of Stelara

interleukin receptor antagonist that binds to and interferes with IL-12 and IL-23

43.

Brand name of tofacitinib

Xeljanz

(can use in moderate-severe UC)

44.

Brand name of ozanimod

Zeposia

45.

MOA of Zeposia

sphingosine 1-phosphate receptor modulator that blocks lymphocytes from exiting the lymph nodes, reducing lymphocytes in the periphery

(can use in moderate-severe UC)

46.

Brand name for natalizumab

Tysabri

(available through REMS)

47.

Brand name of vedolizumab

Entyvio

48.

Discontinue Entyvio and Tysabri is no benefit by

week 14